Legend Biotech Corporation (LEGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Legend Biotech Corporation (LEGN) Healthcare & Pipeline Overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical firm, specializes in developing innovative cell therapies for oncology and other diseases. As a subsidiary of Genscript Biotech, it leverages a lead CAR-T candidate, LCAR-B38M, for multiple myeloma, alongside a pipeline targeting various cancers across global markets.

What Is the Investment Thesis for LEGN?

Legend Biotech Corporation presents an investment thesis centered on its advanced clinical pipeline, particularly LCAR-B38M for multiple myeloma, and its strategic collaboration with Janssen Biotech. The company's focus on innovative cell therapies for oncology represents a high-growth, high-impact segment within biotechnology. With a market capitalization of $3.55B, Legend Biotech is positioned as a significant player in the CAR-T space, despite operating with a negative profit margin of -22.0%, typical for a clinical-stage biopharmaceutical firm heavily investing in R&D. The gross margin of 55.0% indicates strong underlying economics once therapies reach commercialization. Key growth catalysts include the successful progression and potential regulatory approval of LCAR-B38M, which is undergoing comparative evaluation, and the advancement of its diverse early-stage pipeline targeting various cancers and infectious diseases. The collaboration with Janssen Biotech for ciltacabtagene autoleucel provides a de-risking element and potential for significant future revenue streams. However, the inherent risks of clinical trial success, regulatory hurdles, and intense competition in the cell therapy market remain critical considerations for investors.

Based on FMP financials and quantitative analysis

LEGN Key Highlights

Market Capitalization of $3.55B, reflecting its valuation as a clinical-stage biopharmaceutical company with a significant pipeline.

• Profit Margin of -22.0%, indicative of substantial ongoing research and development investments typical for a company in the clinical trial phase.
• Gross Margin of 55.0%, demonstrating strong potential profitability for its therapeutic products upon successful commercialization.
• Beta of 0.35, suggesting relatively lower volatility compared to the broader market, which can be characteristic of certain biotechnology stocks.
• Employs 2600 professionals, underscoring its significant operational scale and commitment to advancing its cell therapy programs.

Who Are LEGN's Competitors?

LEGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LEGN's Key Strengths?

Advanced clinical pipeline with lead CAR-T candidate LCAR-B38M for multiple myeloma in comparative evaluation.

• Strategic collaboration with Janssen Biotech, Inc., for development and commercialization of ciltacabtagene autoleucel.
• Diverse early-stage pipeline targeting various cancers (gastric, T-cell lymphoma, non-Hodgkin's, diffuse large B-cell, acute lymphoblastic leukemia) and infectious diseases.
• Strong gross margin of 55.0% indicating potential profitability upon commercialization.
• Global operational presence across the United States, China, and international markets.

What Are LEGN's Weaknesses?

Operating with a negative profit margin of -22.0%, typical for a clinical-stage company, indicating reliance on funding for R&D.

• High dependence on the success of a limited number of lead product candidates, particularly LCAR-B38M.
• Significant capital expenditure required for ongoing research, development, and clinical trials.
• As a subsidiary of Genscript Biotech Corporation, strategic autonomy might be influenced by the parent company.
• Beta of 0.35 suggests lower market sensitivity, but also potentially less upside during strong market rallies for high-growth sectors.

What Could Drive LEGN Stock Higher?

LEGN catalyst: Successful completion of comparative evaluation for LCAR-B38M in revlimid-refractory multiple myeloma, leading to potential regulatory submission and approval.

• Positive data readouts or advancement of early-stage pipeline candidates for gastric cancer, T-cell lymphoma, or other hematological malignancies into later clinical phases.
• Achievement of development or commercialization milestones under the collaboration agreement with Janssen Biotech, Inc., for ciltacabtagene autoleucel.
• Expansion of therapeutic applications of cell therapies into solid tumors or infectious diseases, marked by entry into human clinical trials.
• Potential for new strategic partnerships or collaborations to further develop and commercialize pipeline assets in specific geographic markets or indications.

What Are the Key Risks for LEGN?

Negative return on equity (-24.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for LCAR-B38M or other pipeline candidates, which could halt development or delay regulatory approval.
• Significant capital requirements and negative profit margin (-22.0%) necessitate continuous funding, posing a risk if capital markets become less favorable.
• Intense competition in the cell therapy and oncology markets from established pharmaceutical companies and emerging biotechs, potentially impacting market share and pricing.
• Regulatory hurdles and delays in obtaining approvals from health authorities (e.g., FDA, EMA, NMPA), which are common in the biopharmaceutical industry.
• Manufacturing complexities and scalability challenges inherent in producing autologous cell therapies, which could limit commercialization capacity and increase costs.

What Are the Growth Opportunities for LEGN?

• Growth opportunity 1: Successful Clinical Development and Commercialization of LCAR-B38M. Legend Biotech's lead candidate, LCAR-B38M, for revlimid-refractory multiple myeloma, represents a significant market opportunity. The global multiple myeloma market is substantial and growing, with a high unmet need for effective treatments for relapsed/refractory patients. Successful completion of its comparative evaluation against standard triplet therapies and subsequent regulatory approvals in key markets like the US and China could unlock significant revenue streams. The timeline for this opportunity is contingent on clinical trial outcomes and regulatory review, potentially within the next few years, establishing Legend Biotech as a key player in the CAR-T space for MM.
• Growth opportunity 2: Expansion of Pipeline into New Oncological Indications. Beyond multiple myeloma, Legend Biotech is actively advancing early-stage autologous product candidates for gastric cancer and T-cell lymphoma in Phase I clinical trials. Additionally, its CAR-T therapies targeting CD20, CD22, and CD19 for non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia represent further avenues for growth. Each of these indications addresses a significant patient population with varying degrees of unmet medical need. Successful progression through clinical phases and eventual commercialization of these therapies would diversify its product portfolio and revenue base, potentially over a 5-10 year horizon.
• Growth opportunity 3: Development in Solid Tumors and Infectious Diseases. Legend Biotech is expanding its therapeutic scope into solid tumors and infectious diseases, with product candidates in both early preclinical and clinical development phases. Solid tumors represent a much larger and more challenging market for cell therapies compared to hematological malignancies, offering immense growth potential if successful. Similarly, developing cell therapies for infectious diseases could open up entirely new market segments. These early-stage programs, while higher risk, offer long-term growth opportunities, with potential clinical milestones emerging over the next 3-7 years, positioning the company for future innovation.
• Growth opportunity 4: Leveraging the Janssen Biotech Collaboration. The significant collaboration with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel, is a critical growth driver. This partnership not only provides shared resources and expertise but also validates Legend Biotech's platform and pipeline. The success of ciltacabtagene autoleucel in the market directly contributes to Legend Biotech's financial performance through milestones and royalties. This collaboration allows Legend Biotech to access Janssen's global commercialization capabilities, accelerating market penetration and maximizing the value of this asset, with ongoing revenue contributions expected as the product gains market share.
• Growth opportunity 5: Geographic Market Expansion. Legend Biotech currently operates across the United States, China, and international markets. As its pipeline candidates, particularly LCAR-B38M, progress towards commercialization, there is a significant opportunity to deepen its market penetration and expand its commercial footprint in these regions. The Chinese market, in particular, offers substantial growth potential given the large patient population and evolving healthcare landscape. Strategic expansion into additional international markets, either independently or through partnerships, could significantly broaden its addressable market and revenue base over the next 3-5 years, capitalizing on global demand for advanced cell therapies.

What Threats Does LEGN Face?

• Risk of clinical trial failures or delays for pipeline candidates, including LCAR-B38M.
• Intense competition from other biopharmaceutical companies developing similar or alternative cell therapies and oncology treatments.
• Stringent and evolving regulatory landscape, potentially leading to delays or non-approvals.
• High costs associated with R&D and manufacturing of cell therapies, impacting financial sustainability.
• Patent challenges or loss of intellectual property protection for its key technologies and products.

What Are LEGN's Competitive Advantages?

• Proprietary cell therapy platform and intellectual property surrounding its CAR-T candidates, particularly LCAR-B38M.
• Advanced clinical pipeline with therapies in various stages of development, creating a potential first-mover advantage in specific indications.
• Strategic collaboration with Janssen Biotech, Inc., providing access to significant resources, expertise, and a global commercialization network.
• Specialized R&D capabilities and expertise in complex cell therapy manufacturing and development.
• Regulatory progress and potential approvals for lead candidates, which are difficult and costly for competitors to replicate.

What Does LEGN Do?

Legend Biotech Corporation, founded in 2014 and based in Somerset, New Jersey, operates as a clinical-stage biopharmaceutical firm and a subsidiary of Genscript Biotech Corporation. The company is dedicated to the discovery, development, and advancement of innovative cell therapies, primarily targeting oncological conditions but also addressing other diseases across the United States, China, and international markets. Its research and development efforts are channeled through various subsidiaries. The cornerstone of Legend Biotech's pipeline is LCAR-B38M, a chimeric antigen receptor (CAR) product specifically engineered for treating multiple myeloma (MM). This lead investigational therapy is currently undergoing a pivotal comparative evaluation against standard triplet therapies in patients who suffer from revlimid-refractory multiple myeloma, representing a significant potential advancement in treatment options for this challenging blood cancer. Beyond its lead candidate, Legend Biotech maintains a robust pipeline of early-stage, autologous product candidates. These include therapies currently in Phase I clinical trials aimed at addressing gastric cancer and T-cell lymphoma, demonstrating the company's commitment to expanding its therapeutic reach. Furthermore, the company is actively developing CAR-T cell therapies designed to target specific antigens such as CD20, CD22, and CD19. These therapies are intended for the treatment of various hematological malignancies, including non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Expanding its therapeutic scope even further, Legend Biotech has product candidates in both early preclinical and clinical development phases that are aimed at solid tumors and infectious diseases, highlighting a broad strategic focus. A critical component of its operational strategy is a significant collaboration with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel, which underscores its ability to forge strategic partnerships to advance its therapeutic programs.

What Products and Services Does LEGN Offer?

• Discovers and develops innovative cell therapies, primarily CAR-T therapies.
• Focuses on treating oncological conditions, including multiple myeloma, gastric cancer, and various lymphomas.
• Conducts clinical trials for lead candidate LCAR-B38M for revlimid-refractory multiple myeloma.
• Develops early-stage autologous product candidates for gastric cancer and T-cell lymphoma.
• Researches CAR-T cell therapies targeting CD20, CD22, and CD19 for non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia.
• Explores product candidates in preclinical and clinical development for solid tumors and infectious diseases.
• Collaborates with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel.
• Operates globally across the United States, China, and other international markets.

How Does LEGN Make Money?

• Generates revenue through collaboration agreements, including milestone payments and potential royalties from partnerships like the one with Janssen Biotech.
• Invests heavily in research and development to advance its pipeline of cell therapies through preclinical and clinical stages.
• Aims to commercialize its proprietary cell therapy products upon regulatory approval, generating sales revenue.
• Leverages its intellectual property and scientific expertise in CAR-T and other cell therapies to create value.
• Functions as a subsidiary of Genscript Biotech Corporation, potentially benefiting from shared resources and strategic direction.

What Industry Does LEGN Operate In?

Legend Biotech Corporation operates within the highly dynamic and innovation-driven Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intense research and development, long product development cycles, and significant regulatory hurdles. The company is specifically positioned in the burgeoning field of cell therapies, particularly CAR-T therapies, which represent a significant advancement in oncology treatment. The global cell therapy market is experiencing robust growth, driven by increasing prevalence of chronic diseases, technological advancements, and rising investments in R&D. Legend Biotech's focus on multiple myeloma, gastric cancer, lymphomas, and solid tumors places it in direct competition with other biopharmaceutical companies developing similar advanced therapeutic modalities. Its clinical-stage status means it is competing for market share and investor confidence based on pipeline strength and clinical trial success, rather than established product sales. The industry landscape is marked by strategic collaborations and partnerships, as evidenced by Legend Biotech's alliance with Janssen Biotech, which are crucial for sharing development costs and leveraging commercialization expertise.

Who Are LEGN's Key Customers?

• Patients suffering from various oncological conditions, including multiple myeloma, gastric cancer, and lymphomas.
• Healthcare providers and oncology centers seeking advanced cell therapy treatments.
• Pharmaceutical and biotechnology partners for collaborative research, development, and commercialization efforts.
• Researchers and academic institutions engaged in cell therapy and oncology research.
• Regulatory bodies that approve and oversee the use of its therapeutic products.

Company Profile

Legend Biotech Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Somerset, US. The company is led by CEO Alan S. Bash. LEGN has traded publicly since 2020.

Legend Biotech Corporation Financial Trajectory

Legend Biotech Corporation (LEGN) reported $387.5M in revenue for Q2 FY2026, reflecting 27.0% growth compared to the prior quarter. The company recorded net income of $33.2M, with diluted EPS of $0.17. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, LEGN averaged $-0.13 in diluted EPS.

How Legend Biotech Corporation Is Valued

Legend Biotech Corporation carries a market capitalization of $3.55B, placing it in the mid-cap category. Analyst price targets span from $28.00 to $78.00, with a consensus of $56.14. At the current price of $19.19, that implies approximately 193% upside potential. Relative to its peer group, LEGN's quantitative score of 34/100 is below the peer average of 65/100.

Return on equity for Legend Biotech Corporation stands at -24.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.6%, the inverse of the P/E and a quick read on earnings relative to price.

Legend Biotech Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.86 places it in the safe zone, indicating low near-term bankruptcy risk.

Legend Biotech Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 86.8% below estimates on average.

Over the past six months, Legend Biotech Corporation insiders filed 5 SEC Form 4 transactions — 4 sales and 1 purchases. On net that is roughly 20K shares disposed (about $258K), a signal worth weighing alongside the fundamentals.

LEGN Financials

LEGN Latest News

LEGN Analyst Consensus

LEGN MoonshotScore

LEGN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources